BMI1 and head and neck squamous cell carcinoma: Moreover, abnormal activation of AP-1 plays a critical role in Bmi-1+ CSC-mediated HNSCC invasive growth, and targeting the tumor bulk and Bmi-1+ CSCs by combination therapy effectively inhibits HNSCC growth and eliminates metastases [31].